# The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

> **NCT05732129** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 29 (estimated)

## Conditions studied

- Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05732129
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03-01
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-31
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2023-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732129, "The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05732129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*